Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Caffeine citrate oral solution

Phase 3

NNICHD Global Network for Women's and Children's Health

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hypoxic-Ischemic Encephalopathy (HIE)Recruiting

Hypoxic-Ischemic Encephalopathy (HIE)Phase 3

Recruiting

Timeline

Expected Milestones

Q3 2030

Phase 3Recruiting

Hypoxic-Ischemic Encephalopathy (HIE)

NCT06855108

Clinical

Trials by Indication[1]

Hypoxic-ischemic Encephalopathy (HIE)1 trial

Caffeine for Hypoxic Ischemic Encephalopathy (CHIME Trial)

Recruiting·NNICHD Global Network for Women's and Children's Health·Phase 3·NCT06855108·830 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Caffeine citrate oral solution. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Caffeine citrate oral solution. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — NICHD Global Network for Women's and Children's Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: NNICHD Global Network for Women's and Children's Health

Related News